Notably, vaccinated B16OVA-bearing mice also treated with the anti-Tim-3 antibody exhibited much slower tumor growth compared with mice with anti-DEC-205-hgp100 vaccination alone (Figure 6A), resulting in substantially smaller tumor sizes compared with unvaccinated mice or mice with only anti-DEC-205-hgp100 vaccination (Figure 6B,C). Here, HAVCR2 is linked to neoplasm.